Hyderabad-based Aragen Life Sciences has signed a Memorandum of Understanding (MoU) with Thermo Fisher Scientific to integrate Gibco™ cell culture media with its contract research, development, and manufacturing organization (CRDMO) capabilities. The collaboration covers process development, scale-up, and GMP manufacturing.
The partnership combines Thermo Fisher’s cell culture media with Aragen’s expertise in establishing robust and scalable processes. It is intended to enable optimized upstream bioprocess development through the use of well-characterized, high-performance media.
According to the company, the integration will streamline media–process fit, reduce variability, and accelerate technology transfer. These efforts are aimed at improving productivity across biologics manufacturing.
The collaboration supports the advancement of biologics and biosimilars from early development through commercial manufacturing by enabling more efficient progression across development stages.
The agreement focuses on end-to-end capabilities, including process development, scale-up, and GMP manufacturing, aligned with Aragen’s CRDMO services.
